ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Polymyalgia Rheumatica (PMR)"

  • Abstract Number: 0740 • ACR Convergence 2024

    Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, seoidin McKittrick3, Robert Harrington4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3University of Limerick, Limerick, Ireland, 4St. James's Hospital, Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Polymyalgia Rheumatica (PMR) is the most common inflammatory rheumatic disease in older adults, and aging has been postulated to be central to its pathophysiology.…
  • Abstract Number: 1618 • ACR Convergence 2024

    Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis

    Vivekanand Tiwari1, chih fang2, Emily Campbell3, Katherine loomba2, Nisha Khubchandani2, shikha shah2 and William Rigby4, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth Hitchcock Medical Center, Lebanon, 3Dartmouth Health, Lebanon, NH, 4Dartmouth-Hitchcock, Norwich, VT

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related conditions that often co-occur.1 Approximately half of all patients with GCA experience PMR…
  • Abstract Number: 0741 • ACR Convergence 2024

    Serum Markers of Disease Activity in Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, seoidin McKittrick3, Robert Harrington4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3University of Limerick, Limerick, Ireland, 4St. James's Hospital, Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: A significant unmet need in Polymyalgia Rheumatica (PMR) is the lack of a disease specific serum biomarker for diagnosis, and monitoring of disease activity.…
  • Abstract Number: 1619 • ACR Convergence 2024

    Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care

    Vivekanand Tiwari1, chih fang2, Katherine loomba2, Nisha Khubchandani2, shikha shah2 and William Rigby3, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth Hitchcock Medical Center, Lebanon, 3Dartmouth-Hitchcock, Norwich, VT

    Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
  • Abstract Number: 1565 • ACR Convergence 2023

    Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months

    Sharon Cowley1, Colm Kirby2, Patricia Harkins3, Richard Conway4 and David Kane5, 1Tallaght University Hospital, Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland

    Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…
  • Abstract Number: 1566 • ACR Convergence 2023

    Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica

    Christine Xu1, Ying Liu1, Jennifer Sloane2, Remco Diab3, Hubert van Hoogstraten1, Hisham Abdallah4, Sreeraj Macha1 and Bhaskar Dasgupta5, 1Sanofi, Bridgewater, NJ, 2Sanofi, Cambridge, MA, 3Sanofi, Rotkreuz, Switzerland, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Anglia Ruskin University, East Anglia, United Kingdom

    Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
  • Abstract Number: 1649 • ACR Convergence 2023

    Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis

    Lara Clarissa Burg1, Christian Dejaco2, Pantelis Karakostas3, Charlotte Behning4, Peter Brossart1 and Valentin Sebastian Schäfer3, 1University Hospital of Bonn, Bonn, Germany, 2Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, 3Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, 4Institute of Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Bonn, Germany

    Background/Purpose: In recent years, ultrasound has become a standard tool in the diagnosis of giant cell arteritis (GCA). Typical findings are increased intima media thickness…
  • Abstract Number: 0027 • ACR Convergence 2023

    Association of HLA-DRB1 and ANKRD55/IL6ST Regions with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank and FinnGen

    Mehmet Hocaoglu1, Jamal Mikdashi2, James Perry2 and Charles Hong2, 1University of Maryland School of Medicine, Pittsburgh, PA, 2University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: The existing literature on the genetics of polymyalgia rheumatica (PMR) is limited to candidate gene studies with small sample sizes. There is a need…
  • Abstract Number: 1869 • ACR Convergence 2023

    FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients

    Andreas Wiggers Nielsen1, Ib Tønder Hansen2, Berit Dalsgaard Nielsen3, Søren Geill Kjær4, Jesper Blegvad-Nissen4, Christian Møller Sørensen3, Ellen-Margrethe Hauge1, Lars Christian Gormsen2 and Kresten Krarup Keller1, 1Aarhus University Hospital, Aarhus, Denmark, 2Aarhus University Hospital, Aarhus N, Denmark, 3Department of Internal Medicine, Horsens, Denmark, 4Diagnostic Centre, Silkeborg, Denmark

    Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients…
  • Abstract Number: 0267 • ACR Convergence 2023

    Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists

    Victor Yang1, Jem Ninan2, David Liew1, Helen Keen3, Catherine Hill4 and Jessica Leung5, 1Austin Health, Heidelberg, Australia, 2University of Adelaide, Adelaide, Australia, 3University of Western Australia, Daglish, Australia, 4The Queen Elizabeth Hospital, Woodville, Australia, 5Austin Health, Preston, Australia

    Background/Purpose: Polymyalgia rheumatica (PMR) is the second-most common inflammatory rheumatic disease but there remains variation amongst rheumatologists in approaches to diagnosis and management. This study…
  • Abstract Number: 1878 • ACR Convergence 2023

    MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study

    Thurkka Rajeswaran1, Emma Harris2, hannah Mathieson1, John Biglands3, Paul Stewart1, Ai Lyn Tan1 and Sarah Mackie4, 1University of Leeds, Leeds, United Kingdom, 2The Open University, Milton Keynes, United Kingdom, 3NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…
  • Abstract Number: 0717 • ACR Convergence 2023

    Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica

    Despoina Michailidou1, Linda Johansson2, Jorge Armando Gonzalez-Chapa1, Ting Wang1, Junmei Chen3, José A. López3, Solbritt Rantapää-Dahlqvist4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Umea University, Umea, Sweden, 3Bloodworks Research Institute, Seattle, WA, 4Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden

    Background/Purpose: Platelets have been suggested to be involved in polymyalgia rheumatica (PMR) pathogenesis with elevated platelet activation observed in early stages of the disease. Upon…
  • Abstract Number: 1890 • ACR Convergence 2023

    Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features

    Emily Martin1, Christopher McMaster1, Saskia Rowson1, Victor Yang1, Aurora Poon1, Bonnia Liu1, Jessica Leung2, Andrew Scott1, David Liew1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Preston, Australia, 3Austin Health, Malvern East, Australia

    Background/Purpose: PET/CT is a highly sensitive and specific test for diagnosing PMR.(1) This study investigated the utility of 18F-FDG whole body PET/CT in patients presenting…
  • Abstract Number: 0718 • ACR Convergence 2023

    Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting

    Jeffrey Curtis1, Lita Araujo2, Stefano Fiore2, Sebastian Sattui3, John Stone4, Kerri Ford2 and Fenglong Xie5, 1University of Alabama at Birmingham, Birmingham, AL, 2Sanofi, Cambridge, MA, 3University of Pittsburgh, Pittsburgh, PA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 5Illumination Health, Hoover, AL

    Background/Purpose: The burden of continuing glucocorticoids (GCs) in patients with polymyalgia rheumatica (PMR) who have an inadequate response (IR)to GCs has not been evaluated.Methods: An…
  • Abstract Number: 2392 • ACR Convergence 2023

    Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis

    andre ramon1, helene Greigert2, corentin Richard3, claudie cladière4, coraline genet5, marion ciudad6, georges tarris7, laurent martin8, louis arnould9, catherine creuzot-garcher10, paul ornetti11, Sylvain Audia12, romain boidot3, jean-Francis Maillefert11, Bernard Bonnotte2 and Maxime Samson2, 1Department of Rheumatology, Dijon University Hospital, Dijon, France, 2Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 3Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, 4INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, 5INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 6INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 7Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, 8Department of Pathology, Dijon University Hospital, Dijon, France, 9Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, 10Department of Ophthalmology, Dijon University Hospital, Dijon, France, 11Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, 12Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France

    Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology